ALLGF News and Press, Alligator Bioscience AB From 10/24/19

STOCKHOLM , Oct. 24, 2019 /PRNewswire/ -- " We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 substance to, with or without a new partner, bring ADC-1013 into Phase II clinical trials next year. In total, w...

Deals and Financings Biotheus, a China biopharma based in Zhuhai, Guangdong, announced a $142 million agreement to in-license greater China rights for a TNFR antibody developed by Alligator Bioscience of Stockholm (ALLGF). Formed in 2018, Biotheus will have rights for up to three bi-spec...

LUND, Sweden , July 31, 2019   /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) , today announces that it has regained exclusive, worldwide rights from Janssen Biotech Inc. to develop and commercialize the CD40 agonistic antibody, ADC-1013 (JNJ-64457107), its lead tum...

- Competitive safety data for ADC-1013 STOCKHOLM , July 11, 2019 /PRNewswire/ --  Significant events April-June Janssen presented data from the clinical Phase I study with ADC-1013 indicates good safety and shows initial signs of clinical effect. Study design and ...

STOCKHOLM , May 16, 2019   /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX)   , today announces that the outline of the ongoing Phase I study with the bispecific drug candidate ATOR-1015 will be showcased at the American Society of Clinical Oncology (ASCO) Annua...

LUND, Sweden , May 16, 2019 /PRNewswire/ --  Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Janssen Biotech, Inc. (Janssen) will present data from a Phase I clinical study of ADC-1013 (JNJ-7107) at the upcoming ASCO Annual meeting held in Chicago on May 31- ...

Alligator Bioscience ( OTC:ALLGF ): Q1 GAAP EPS of SEK5.94. More news on: ALLIGATOR BIOSCIENCE AB, Earnings news and commentary, , Read more ...

STOCKHOLM , April 17, 2019 /PRNewswire/ --  Significant events January-March First patient dosed in Phase I clinical study of ATOR-1015. New preclinical data presented demonstrating strong anti-tumor effects for the 4-1BB antibody ATOR-1017. Alligator Bioscience launched...

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail . STOCKHOLM , April 10, 2019 /PRNewswire/ -- The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invi...

LUND, Sweden , March 18, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) , today announce that they will present preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to be held in London on March 18-22, 2019 . ATOR-...